Jump to main content.

Di(2-ethylhexyl)adipate Quickview (CASRN 103-23-1)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Di(2-ethylhexyl)adipate

File First On-Line: 10/01/1989; Last Significant Revision: 07/01/1992

Category (section)
Last Revised
Oral RfD Assessment Yes 07/01/1992
Inhalation RfC Assessment No
Carcinogenicity Assessment Yes 08/01/1991
  • 103-23-1
  • Adipol 2EH
  • BEHA
  • bis(2-Ethylhexyl) adipate
  • bis-(2-Ethylhexyl)ester kyseliny adipove [Czech]
  • Bisoflex DOA
  • DEHA
  • Di-2-ethylhexyl adipate
  • DOA
  • Effemoll DOA
  • Effomoll DOA
  • more...
Di(2-ethylhexyl)adipate Source Documents
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size NOAEL : 1.70 x102 mg/kg-day 300 6 x10-1 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • C (Possible human carcinogen)
  • Weight-of-Evidence Narrative:
    • Based on an absence of human data and increased incidence of liver tumors in female mice. Except for a positive dominant lethal assay, there was no evidence of genotoxicity; this compound does, however, exhibit structural relationships to other nongenotoxic compounds classified as probable and possible human carcinogens.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Oral Slope Factor(s)
Extrapolation Method
1.2 x10-3 per mg/kg-day Linearized multistage procedure, extra risk
Drinking Water Unit Risks
3.4x10-8 per µg/L
Risk Level
E-4 (1 in 10,000) 3x103 µg/L
E-5 (1 in 100,000) 3x102 µg/L
E-6 (1 in 1,000,000) 3x101 µg/L

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.